{"id":"NCT03149003","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy","officialTitle":"A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-08","primaryCompletion":"2021-08-30","completion":"2021-08-30","firstPosted":"2017-05-11","resultsPosted":"2023-01-30","lastUpdate":"2023-11-15"},"enrollment":221,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Glioblastoma"],"interventions":[{"type":"DRUG","name":"DSP-7888 Dosing Emulsion","otherNames":["adegramotide and nelatimotide"]},{"type":"DRUG","name":"Bevacizumab","otherNames":["Avastin"]}],"arms":[{"label":"Arm 1: DSP-7888 Dosing Emulsion plus Bevacizumab","type":"EXPERIMENTAL"},{"label":"Arm 2: Bevacizumab","type":"ACTIVE_COMPARATOR"}],"summary":"This is an event driven, adaptive design, a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 3 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) following treatment with first line therapy consisting of surgery and radiation with or without chemotherapy.","primaryOutcome":{"measure":"Number of Participants Who Experienced a Dose-limiting Toxicity","timeFrame":"Dose-limiting toxicity will be evaluated and applied from Day 1 through Day 29","effectByArm":[{"arm":"Part 1 - Arm 1: DSP-7888 Dosing Emulsion Plus Bevacizumab","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":24},"locations":{"siteCount":61,"countries":["United States","Canada","Japan","South Korea","Taiwan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":4},"commonTop":["Injection site reaction","Hypertension","Headache","Fatigue","Seizure"]}}